A mouse-based assay for the pre-clinical neurovirulence assessment of vaccinia virus-based smallpox vaccines

Biologicals

Volumn 38, Issue 2, 2010, Pages 278-283

  Zhang, Cheryl X ^a   Sauder, Christian ^a   Malik, Tahir ^a   Rubin, Steven A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Mouse; Neurovirulence; Safety testing; Smallpox; Vaccine; Vaccinia

Indexed keywords

SMALLPOX VACCINE; UNCLASSIFIED DRUG; VIRUS BASED SMALLPOX VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; CHICK EMBRYO; CONTROLLED STUDY; DRUG SCREENING; EMBRYO; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; TOXICITY TESTING; VACCINIA VIRUS; VERO CELL; VIRUS CONCENTRATION; VIRUS CULTURE; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALS; ANIMALS, NEWBORN; BRAIN; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CHICK EMBRYO; DRUG EVALUATION, PRECLINICAL; ENCEPHALOMYELITIS, ACUTE DISSEMINATED; MICE; MODELS, ANIMAL; SMALLPOX VACCINE; TIME FACTORS; VACCINIA; VACCINIA VIRUS; VERO CELLS; VIRULENCE; VIRUS REPLICATION;

MUS; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 77950691264     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2009.09.007     Document Type: Article

References (33)

1. 2004 update: adverse events following civilian smallpox vaccination-United States. MMWR Morb Mortal Wkly Rep 2003, 53:106-107.
2. Abrahams B.C., Kaufman D.M. Anticipating smallpox and monkeypox outbreaks: complications of the smallpox vaccine. Neurologist 2004, 10:265-274.
3. Belongia E.A., Naleway A.L. Smallpox vaccine: the good, the bad, and the ugly. Clin Med Res 2003, 1:87-92.
4. Bradbury J. USA to increase smallpox vaccine stockpile. Lancet Infect Dis 2001, 1:290.
5. Breman J.G., Henderson D.A. Poxvirus dilemmas-monkeypox, smallpox, and biologic terrorism. N Engl J Med 1998, 339:556-559.
6. Carroll M.W., Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997, 238:198-211.
7. Cohen J. Bioterrorism. Smallpox vaccinations: how much protection remains?. Science 2001, 294:985.
8. Frey S.E., Newman F.K., Kennedy J.S., Sobek V., Ennis F.A., Hill H., et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine 2007, 25:8562-8573.
9. Fulginiti V.A. Risks of smallpox vaccination. J Am Med Assoc 2003, 290:1452.
10. Fulginiti V.A., Papier A., Lane J.M., Neff J.M., Henderson D.A. Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis 2003, 37:251-271.
11. Gurvich E.B., Vilesova I.S. Vaccinia virus in postvaccinal encephalitis. Acta Virol 1983, 27:154-159.
12. Hayasaka D., Ennis F.A., Terajima M. Pathogeneses of respiratory infections with virulent and attenuated vaccinia viruses. Virol J 2007, 4:22.
13. Henderson D.A. Smallpox eradication. Public Health Rep 1980, 95:422-426.
14. Henderson D.A., Inglesby T.V., Bartlett J.G., Ascher M.S., Eitzen E., Jahrling P.B., et al. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. J Am Med Assoc 1999, 281:2127-2137.
15. Hwang H.S. J Prev Med Public Health 2008, 41:209-213.
16. Institute of Laboratory Animal Resources, Commission on Life Sciences National Research Council Guide for the care and use of laboratory animals 1996, National Academy Press, p. 1-140. http://oacu.od.nih.gov/regs/index.htm.
17. International Association for Biologicals IABs scientific workshop on neurovirulence tests for live virus vaccines, January 31-February 1, 2005, Geneva. Biologicals 2006, 34:233-236.
18. Kretzschmar M., Wallinga J., Teunis P., Xing S., Mikolajczyk R. Frequency of adverse events after vaccination with different vaccinia strains. PLoS Med 2006, 3:e272.
19. Lane J.M., Ruben F.L., Abrutyn E., Millar J.D. Deaths attributable to smallpox vaccination, 1959 to 1966, and 1968. J Am Med Assoc 1970, 212:441-444.
20. Li Z., Rubin S.A., Taffs R.E., Merchlinsky M., Ye Z., Carbone K.M. Mouse neurotoxicity test for vaccinia-based smallpox vaccines. Vaccine 2004, 22:1486-1493.
21. Mora L.F., Khan A.H., Sperling L.S. Cardiac complications after smallpox vaccination. Southampt Med J 2009.
22. Morita M., Aoyama Y., Arita M., Amona H., Yoshizawa H., Hashizume S., et al. Comparative studies of several vaccinia virus strains by intrathalamic inoculation into cynomolgus monkeys. Arch Virol 1977, 53:197-208.
23. Mortimer P.P. The new cell culture smallpox vaccine should not be offered to the general population. Rev Med Virol 2003, 13:17-20.
24. Parrino J., McCurdy L.H., Larkin B.D., Gordon I.J., Rucker S.E., Enama M.E., et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 2007, 25:1513-1525.
25. Payne L.G. Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J Gen Virol 1980, 50:89-100.
26. Rockoff A., Spigland I., Lorenstein B., Rose A.L. Postvaccinal encephalomyelitis without cutaneous vaccination reaction. Ann Neurol 1979, 5:99-101.
27. Saito T., Fujii T., Kanatani Y., Saijo M., Morikawa S., Yokote H., et al. Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA 2009, 301:1025-1033.
28. Smee D.F., Bailey K.W., Wong M.H., Sidwell R.W. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res 2001, 52:55-62.
29. Smee D.F., Hurst B.L., Wong M.H., Glazer R.I., Rahman A., Sidwell R.W. Efficacy of N-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virus. Antiviral Res 2007, 76:124-129.
30. Varkey P., Poland G.A., Cockerill F.R., Smith T.F., Hagen P.T. Confronting bioterrorism: physicians on the front line. Mayo Clin Proc 2002, 77:661-672.
31. WHO Global smallpox vaccine reserve: report by the secretariat 2004, EB115/36, p. 1-3.
32. WHO Smallpox, bioterrorism and the World Health Organization 2006, p. 1-9.
33. Wiser I., Balicer R.D., Cohen D. An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies. Vaccine 2007, 25:976-984.